Marc Malouf, MD
Ophthalmology · Camp Springs, MDNPI 1821318841
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,455 of the $4,521 with a category attached, or 76.4%. 23 manufacturers reported payments, led by Alcon at 42.6% of the total.
Across 128 payments — averaging $35.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Tarsus Pharmaceuticals, Inc.$616
- Bausch & Lomb, A Division Of Bausch Health US, LLC$321
- Bausch & Lomb Americas Inc.$319
- NEW World Medical,inc.$226
- Sun Pharmaceutical Industries Inc.$138
- plus $975 from 17 others
Across 6 payments — averaging $7163.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$43K
What the payments were for
- Speaking & faculty fees$281%
- Travel & lodging$97822%
- Food & beverage$3,45576%
- Education$241%
- Gifts$351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 39 | $1,924 |
| Tarsus Pharmaceuticals, Inc. | 16 | $616 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 11 | $321 |
| Bausch & Lomb Americas Inc. | 11 | $319 |
| NEW World Medical,inc. | 2 | $226 |
| Sun Pharmaceutical Industries Inc. | 6 | $138 |
| Rxsight Inc | 5 | $117 |
| AbbVie(2 entities) | 5 | $117 |
| Carl Zeiss Meditec USA, Inc. | 1 | $106 |
| Kala Pharmaceuticals, Inc. | 6 | $105 |
| Novartis | 4 | $79 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $72 |
| Mallinckrodt Hospital Products Inc. | 3 | $69 |
| Biotissue Holdings Inc. | 2 | $42 |
| Amgen | 2 | $41 |
| Oyster Point Pharma, Inc. | 2 | $38 |
| Omeros Corporation | 2 | $37 |
| Eyevance Pharmaceuticals LLC | 2 | $35 |
| Carl Zeiss Meditec, Inc. | 1 | $32 |
| Harrow Eye, LLC | 1 | $25 |
| Ocular Therapeutix, Inc. | 1 | $24 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Aerie Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LenSx$1,126
- XDEMVY$130
- LOTEMAX SM$125
- ARGOS$116
- CIRRUS HD-OCT$106
How this compares
$4,521 in reported general payments places this provider in the 75th percentile of 493 ophthalmology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 126 | $177,436 |
| RestasisCyclosporine | 59 | $61,562 |
| XdemvyLotilaner | 25 | $47,447 |
| TyrvayaVarenicline Tartrate | 12 | $19,797 |
| LumiganBimatoprost | 23 | $12,211 |
| Prednisolone Acetate | 76 | $6,469 |
| Cyclosporine | 23 | $5,870 |
| CombiganBrimonidine Tartrate/Timolol | 12 | $4,229 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 24 | $3,639 |
| Latanoprost | 257 | $2,996 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 133 | $2,861 |
| Brimonidine Tartrate | 30 | $2,686 |
| Travoprost | 13 | $2,410 |
| ErythromycinErythromycin Base | 132 | $1,275 |
| Ketorolac Tromethamine | 24 | $1,018 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra | $319 | $177,436126 claims |
| AbbVieRestasis, Lumigan, Combigan | $117 | $78,00294 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $616 | $47,44725 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $38 | $19,79712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 493 ophthalmology providers in Maryland.
Other ophthalmology in Camp Springs
- Alfred SommerBaltimore$2.9M
- Richard AdlerBaltimore$2.7M
- Peter McDonnellBaltimore$1.4M
- Esen AkpekBaltimore$782K
- Lisa FeulnerBel Air$434K
- Allen HuHagerstown$379K
- Susan BresslerLutherville$341K
- Renee BovelleGlenn Dale$292K
- Neil BresslerBaltimore$265K
- Scott LaborwitTowson$204K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.